Post-Physical Therapy Extension of In-Home Dynamic Standing Table Use in Parkinson Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of Parkinson's disease. PD diagnosis following the UK Parkinson's Disease Society Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD, consistent with the typical nigrostriatal denervation pattern on VMAT2.
- Hoehn and Yahr stages 2-4 and/or presence of PIGD features, such as history of (near) falls, slow gait, and/or freezing of gait.
- Available space to place table in their home (approximately 6 ft x 5 ft area).
Exclusion Criteria:
- Inability to stand or walk without an assistive device.
- History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain.
- History of significant symptomatic cardiovascular or pulmonary disease.
- History of active symptomatic rheumatic arthritis.
- History of stroke or other focal brain conditions with residual sensorimotor deficits interfering with stance functions.
- History of chronic pain syndrome requiring daily narcotic analgesics.
- Evidence of dementia.
- Venous stasis or severe varicosities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: In-Home Standing Table
Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the "neutral body positioning" guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls. In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use. |
The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
|
|
No Intervention: Standard of Care
this group will received standard of care only, which is weekly group exercise sessions during a 16-week period.
Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in stride velocity during the instrumented Timed Up and Go test from week 6 to week 23
Time Frame: At week 6 (post-physical therapy); at week 23 (post 16-week table intervention)
|
Instrumented Timed Up and Go, Subject starts in seated position rises from chair and walks 3 meters, then returns to chair in a seated position
|
At week 6 (post-physical therapy); at week 23 (post 16-week table intervention)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nicolaas Bohnen, MD PhD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00118467
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
NCT07148700RecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s Disease
-
NCT07217054RecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s Disease
-
NCT06680830RecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)
-
NCT07554833Not yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s Disease
-
NCT07312110RecruitingParkinson Disease (PD) | Parkinson s Disease
-
NCT07630792Not yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
NCT07204652RecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)
-
NCT06705517RecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)
-
NCT02511015CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
-
NCT07567794Not yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons Disease
Clinical Trials on Dynamic Standing Table
-
NCT02127606UnknownSpinal Cord Injury | Spasticity
-
NCT03944564RecruitingPain, Acute | Work-Related Condition | Muscle Tone Abnormalities | Sensory Deficit
-
NCT07543861Recruiting
-
NCT04410055UnknownCognitive Change | Aging | Diabete Mellitus
-
NCT02047617CompletedPatients Are Recruited From One Thoracic and Cardiac Surgery ICU
-
NCT02755415Unknown
-
NCT05953649Not yet recruitingCritically Ill | Mechanical Ventilation | Early Mobilization | Diaphragm Dysfunction
-
NCT06557837CompletedDegenerative Spine Disease | Sagittal Balance
-
NCT02813941Completed
-
NCT04831372Active, not recruitingOsteoarthritis, Hip | Arthroplasty, Replacement, Hip